ClinicalTrials.gg
CompletedNCT02175394Updated Jul 8, 2014

Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects

A Phase 1 interventional study of Microgynon® and BI 1356 in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The objective was to investigate the effect of multiple oral doses of 5 mg BI 1356 on the steady-state pharmacokinetics of ethinylestradiol (EE) and levonorgestrel (LNG), the components of Microgynon®

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy premenopausal female subjects as determined by the results of screening based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), heart rate (HR)), 12-lead (ECG), clinical laboratory tests
  • Age 18 - 40 years
  • 18.5 - 27 kg/m2 (Body Mass Index)
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
  • Gynaecological examination without relevant findings

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination deviating from normal and of clinical relevance. Systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg
  • Any evidence of a concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to drug or its )
  • Intake of drugs with a long half-life (greater than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to day 1 or during the trial
  • Use of antibiotics and drugs known to inhibit or induce cytochrome P450 enzymes, especially , within one month prior to study day 1 or during the trial (CYP3A4 inhibitors are for example azole antimycotics, macrolides, CYP3A inducers are for example St. John's Wort or certain anticonvulsants)
  • Participation in another trial with an drug within two months prior to day 1 or during the trial
  • Regular smokers of more than two cigarettes daily
  • Drug or alcohol abuse (more than 20 g alcohol/day)
  • Blood donation (more than 100 mL within four weeks prior to day 1)
  • Excessive physical activities within 48 hours prior to day 1)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of trial site
  • Positive pregnancy test, pregnancy or planning to become pregnant within 2 months of study completion, or lactation
  • No use of an additional method until 6 weeks after last study drug administration, i.e. barrier method, sexual abstinence, non-hormone-containing intrauterine device (IUD), surgical sterilisation (incl. hysterectomy) or vasectomized partner
  • Use of oral contraceptive-containing intrauterine device, depot injection or contraceptive implants
  • Existing or a history of confirmed venous thromboembolism (VTE), family history of idiopathic VTE and other known risk factors for VTE. Existing or previous arterial thrombotic or embolic processes, conditions which predispose to them e.g. disorders of the clotting processes, valvular heart disease and atrial fibrillation
  • Relevant varicosis
  • History of migraine
  • History of liver disease, i.e. disturbances of liver function, jaundice or persistent itching during a previous pregnancy, Dubin-Johnson syndrome, Rotor syndrome, previous or existing liver tumours
  • Clinically relevant cycle anomalies and dysmenorrhoea within the last 12 months
  • Usual menstrual cycle duration outside of a 26-32 days range
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Active comparator
    Microgynon®

    Microgynon® once daily during period 1 (day 1 to day 14)

    Drug: Microgynon®

  • Experimental
    Microgynon® and BI 1356

    Microgynon® combined with BI 1356, once daily during period 2 (day 15 to day 21)

    Drug: Microgynon® · Drug: BI 1356

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of ethinylestradiol and levonogestrel (Microgynon®) in plasma over the dosing interval at steady-state (AUCτ,ss)

    Time frame: On day 14 and on day 21

  2. Maximum measured concentration of ethinylestradiol and levonogestrel (Microgynon®) in plasma at steady state (Cmax,ss)

    Time frame: On day 14 and on day 21

Secondary outcomes

  1. Time from last dosing to the maximum measured concentration of EE and LNG in plasma at steady state (tmax,ss)

    Time frame: Up to day 22 after start of treatment

  2. Apparent clearance of EE and LNG in plasma following extravascular administration at steady state (CL/F,ss)

    Time frame: Up to day 22 after start of treatment

  3. Apparent volume of distribution of EE and LNG during the terminal phase λz at steady state following extravascular administration (Vz/F,ss)

    Time frame: Up to day 22 after start of treatment

  4. Terminal half-life of EE and LNG in plasma at steady state (t1/2,ss)

    Time frame: Up to day 22 after start of treatment

  5. Terminal rate constant of EE and LNG in plasma at steady state (λz,ss)

    Time frame: Up to day 22 after start of treatment

  6. Mean residence time of EE and LNG in the body at steady state after oral administration (MRTpo,ss)

    Time frame: Up to day 22 after start of treatment

  7. Pre-dose plasma concentrations of EE and LNG for attainment of steady state

    Time frame: Up to day 21 after start of Microgynon® treatment

  8. Pre-dose plasma concentration of BI 1356 for attainment of steady state

    Time frame: Day 15 up to 7 days after start of BI 1356 treatment (day 21)

  9. Plasma concentration of BI 1356

    Time frame: Day 21

  10. Number of patients with adverse events

    Time frame: Up to 14 weeks

  11. Number of patients with clinically relevant changes in vital signs (BP, HR)

    Time frame: Up to 14 weeks

  12. Number of patients with clinical relevant changes in laboratory evaluation (haematology, clinical chemistry and urinalysis)

    Time frame: Up to 14 weeks

  13. Number of patients with clinically relevant changes in ECG recordings

    Time frame: Up to 14 weeks

  14. Assessment of global tolerability by the investigator, a 4-point scale

    Time frame: Up to day 14 after last administration of study drug on day 21

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008 and a primary completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2014
First posted
Jun 26, 2014
Start
Jul 2008
Primary completionActual
Oct 2008
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02175394
Responsible party
Sponsor
First posted
Jun 26, 2014
Start date
Jul 2008
Primary completion
Oct 2008
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion